At the Annual General Meeting of the Bình Định Pharmaceutical Equipment Joint Stock Company (Bidiphar, stock code DBD), the company announced a revenue target of 2 trillion VND for 2025, with pre-tax profits of 335 billion VND. In Q1 2025, Bidiphar’s revenue rose by 25%, and profits increased by 20%. The company leads the cancer drug market in Vietnam and ranks second in the dialysis market. Bidiphar is expanding its product portfolio and investing in research and development. The company is striving to increase local sourcing of materials, with 90% still being imported. DBD will also develop its distribution network through hospitals and pharmacies, facing competition from modern pharmacy chains. An investment of 840 billion VND is allocated for a sterile drug manufacturing plant expected to complete by 2026-2027. Bidiphar has received GMP-WHO certification for its injectable and tablet production lines. The export growth plan is limited due to high standards from partners and price competition. The company prioritizes the domestic market for development.
Leave a Reply